TG Therapeutics’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

TG Therapeutics focused on the development of novel, targeted agents for the treatment of various hematologic malignancies and autoimmune disorders. Read more

Michael S. Weiss's photo - Chairman & CEO of TG Therapeutics

Chairman & CEO

Michael S. Weiss

CEO Approval Rating

89/100

Founded:

1993

Status:

PublicNASDAQTGTX

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Trusted Tablets Online Pharmacy is one of TG Therapeutics's top competitors. Trusted Tablets Online Pharmacy was founded in 2007, and its headquarters is in Larnaca, Larnarca District. Trusted Tablets Online Pharmacy competes in the Pharmaceuticals field. Trusted Tablets Online Pharmacy has 219 more employees than TG Therapeutics.

High Times is TG Therapeutics's #2 rival. High Times was founded in 1974 in Los Angeles, California. High Times competes in the Publishing industry. High Times generates $14.6M more revenue than TG Therapeutics.

Ubiquiti is a top competitor of TG Therapeutics. Ubiquiti is a Public company that was founded in New York, New York in 2005. Ubiquiti operates in the Computers, Peripherals, Networking and Electronic Equipment industry. Ubiquiti has 916 more employees vs. TG Therapeutics.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Eli Lilly a competitor of TG Therapeutics?

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$ < 1M

TG Therapeutics's revenue is the ranked 9th among it's top 10 competitors. The top 10 competitors average 5.9B. Over the last four quarters, TG Therapeutics's revenue has decreased by 0%. Specifically, in Q2 2020's revenue was $ < 1M; in Q1 2020, it was $ < 1M; in Q4 2019, it was $ < 1M; in Q3 2019, TG Therapeutics's revenue was $ < 1M.

Acquisitions

No recent acquisitions found related to TG Therapeutics

TG Therapeutics Funding History

$10M$13.7M$26.9M$36.1M$38.3M$40.1M$43.1M$128.1M

Since TG Therapeutics was founded in 1993, it has participated in 11 rounds of funding. In total TG Therapeutics has raised $128.1M. TG Therapeutics' last funding round was on Feb 2019 for a total of $85.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Corporate Round
Feb 2019
$85M
-
Private Placement
Apr 2010
$3M
-
Private Placement
Feb 2009
$1.7M
-
Private Placement
Dec 2008
$1.3M
-
Private Placement
Nov 2008
$1M
-

Total Funding: $128.1M

Since TG Therapeutics was founded in 1993, it has participated in 11 rounds of funding. In total TG Therapeutics has raised $128.1M. TG Therapeutics' last funding round was on Feb 2019 for a total of $85.0M

Investments

No recent investments found related to TG Therapeutics

TG Therapeutics News

August 13, 2020Endpoints News

TG Therapeutics scores priority review for PI3K inhibitor; Galapagos searches for IBD targets in new pact

TG Therapeutics' pitch for umbralisib as a safer PI3Kδ inhibitor has convinced the FDA to put it on t... See more »
July 5, 2020The Markets Daily

Brokerages Expect TG Therapeutics Inc (NASDAQ:TGTX) to Announce -$0.31 Earnings Per Share

Analysts predict that TG Therapeutics Inc (NASDAQ:TGTX) will announce ($0.31) earnings per share (EPS... See more »
June 18, 2020The Pharma Letter

TG Therapeutics completes rolling submission of NGA for umbralisib

TG Therapeutics has announced the completion of the rolling submission of a New Drug Application (NDA... See more »
June 12, 2020Benzinga

TG Therapeutics Announces Data Presentations at the 25th European Hematology Association (EHA) Annual Congress

NEW YORK, June 12, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), today announced data... See more »
June 11, 2020Themarketsdaily

Analysts Expect TG Therapeutics Inc (NASDAQ:TGTX) Will Announce Earnings of -$0.34 Per Share

Wall Street brokerages predict that TG Therapeutics Inc (NASDAQ:TGTX) will report ($0.34) earnings pe... See more »
June 9, 2020MarketScreener

TG Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

(marketscreener.com) NEW YORK, June 09, 2020 -- TG Therapeutics, Inc. , today announced that Michael ... See more »

TG Therapeutics Press Releases

March 9, 2020GlobeNewswire

TG Therapeutics Announces Data Presentations at the Upcoming American Academy of Neurology 72nd Annual Meeting

NEW YORK, March 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced th... See more »
September 30, 2019StreetInsider

TG Therapeutics Announces Publication of Clinical Data from the Phase I/Ib Combination Trial of Ublituximab and Umbralisib ("U2") in Blood

U2 combination was generally well-tolerated with relatively low rates of immune-mediated toxicities C... See more »
August 26, 2019GlobeNewswire

TG Therapeutics Mourns the Loss of Board Member, Mark Schoenebaum, MD

NEW YORK, Aug. 26, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) announced with great... See more »
May 10, 2019GlobeNewswire

TG Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results

Conference Call to be held today, Friday, May 10, 2019 at 8:00 AM ETConference Call to be held today,... See more »
May 7, 2019streetinsider

TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71st Annual Meeting

NEW YORK, May 07, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical ... See more »
April 5, 2019StreetInsider

TG Therapeutics to Present at the 18th Annual Needham Healthcare Conference

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive ... See more »
November 26, 2018GlobalNewswire

Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuit... See more »

Social Statistics

Headquarters

2 Gansevoort Street 9th Floor

New York, New York10014

212-554-4484

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

TG Therapeutics focused on the development of novel, targeted agents for the treatment of various hematologic malignancies and autoimmune disorders. TG Therapeutics was founded in 1993. TG Therapeutics' headquarters is located in New York, New York, U...

CEO

TG Therapeutics's Chairman & CEO, Michael S. Weiss, currently has an approval rating of 89%. TG Therapeutics's primary competitors are Trusted Tablets Online Pharmacy, High Times & Ubiquiti.

Website

tgtherapeutics.com

Frequently Asked Questions about TG Therapeutics

  1. When was TG Therapeutics founded?

    TG Therapeutics was founded in 1993
  2. Who is TG Therapeutics's CEO?

    TG Therapeutics's CEO is Michael S. Weiss
  3. How much revenue does TG Therapeutics generate?

    TG Therapeutics generates $ < 1M in revenue
  4. How much funding does TG Therapeutics have?

    TG Therapeutics has historically raised $128.1M in funding
  1. Where is TG Therapeutics's headquarters?

    TG Therapeutics's headquarters is in New York New York, USA
  2. How many employees does TG Therapeutics have?

    TG Therapeutics has 105 employees
  3. Who are TG Therapeutics's competitors?

    TG Therapeutics's top competitors are Trusted Tablets Online Pharmacy, High Times, Ubiquiti